Dr Shannon E Boye, Co-Founder and Chief Scientific Officer of Atsena Therapeutics, writes about the company's journey to the clinic for a challenging ocular gene therapy target. I have worked for nearly 20 years across academia and the biopharmaceutical industry to develop gene therapies for inherited retinal diseases. I met Sanford Boye, my other half in life and in science, in the lab. If you name any inherited retinal disease, the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!